Lyra therapeutics advances phase 2 beacon clinical trial of lyr-220 in post-surgical chronic rhinosinusitis patients to randomized stage of study

21-point (37%) mean improvement in snot-22 total score at six weeks during the uncontrolled part 1 stage of the 24-week beacon trial first patient dosed in the randomized, part 2 stage of the beacon trial the lyr-220 program in post-surgical patients is in addition to lyr-210 which is in phase iii for surgically naÏve crs patients. watertown, mass.
LYRA Ratings Summary
LYRA Quant Ranking